Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown

Denmark on Friday slashed its annual growth forecast to 1.4% from 3%, in large part due to weaker expectations for pharmaceutical giant Novo Nordisk.

Denmark has recorded strong annual growth in recent years, with its economy expanding 3.7% last year after getting a major boost from pharmaceutical exports.

Danish pharma giant Novo Nordisk makes blockbuster weight management drugs Ozempic and Wegovy.

The economy ministry noted that Denmark's U.S. exports fell significantly in early 2025 after a huge spike in late 2024, due to both inventory build-up and increased competition in the weight loss drug market, which has seen Novo lose market share. Generic medicines are also squeezing its sales opportunities in the U.S., the ministry said.

Pharmaceuticals are now expected to contribute just 1.3 percentage points to Denmark's goods exports growth this year, down from 8.1 percentage points in 2024. Total goods export growth is projected to fall to 2.7% in 2025 from 10.5% the previous year.

Europe's pharmaceutical sector has been rocked this year by the threat of sky-high U.S. tariffs, though some certainty has now been provided by the EU-U.S. trade deal.

The Danish economy ministry said U.S. tariffs had weighed on its growth forecast, while a statistical revision showed that real GDP expanded less in 2021-2024 than previously calculated.

“Growth in the first quarter of 2025 has also been weaker than previously expected. Together with the American tariff increases and downwardly adjusted expectations for the pharmaceutical industry, this has given rise to a significant downward adjustment of the estimate for GDP growth in 2025,” it said in a statement, according to Google Translate.